SHIELD THERAPEUTICS PLC — AGM Information 2019

Jun 13, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1349C

Shield Therapeutics PLC

13 June 2019

Shield Therapeutics plc

("Shield" or the "Group")

Result of 2019 Annual General Meeting

London, UK, 13th June 2019:        Shield Therapeutics plc (LSE:STX), a commercial stage, specialty pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces the results of the proxy vote for each of the resolutions set out in the Notice of AGM.

The following table shows the votes cast on each resolution:

	VOTES FOR	%	VOTES AGAINST	%	VOTES TOTAL	% of ISC VOTED	VOTES WITHHELD
1	91,099,593	99.16	769,230	0.84	91,868,823	78.46%	0
2	86,706,679	94.40	5,144,503	5.60	91,851,182	78.45%	17,641
3	91,079,163	99.14	789,611	0.86	91,868,774	78.46%	49
4	86,767,461	94.45	5,101,313	5.55	91,868,774	78.46%	49
5	91,868,823	100.00	0	0.00	91,868,823	78.46%	0
6	85,998,231	93.61	5,870,543	6.39	91,868,774	78.46%	49
7	91,065,998	99.14	790,943	0.86	91,856,941	78.45%	11,882
8	91,835,228	99.97	29,777	0.03	91,865,005	78.46%	3,818
9	74,183,338	80.76	17,677,421	19.24	91,860,759	78.45%	8,064
10	74,179,520	80.76	17,677,421	19.24	91,856,941	78.45%	11,882
11	17,401,749	18.94	74,455,192	81.06	91,856,941	78.45%	11,882
12	91,856,941	100.00	0	0.00	91,856,941	78.45%	11,882

The Board reports that resolutions 1 to 9 passed as ordinary resolutions and resolutions 10 and 12 were passed as special resolutions. Special resolution 11 was not passed, however resolutions 9 and 10 were obtained which authorise the Company to allot equity share capital including the right to issue up to 5% of issued share capital disapplying pre-emption rights.

Notes

1.   Percentage of shares voted: 78.46% (Number of shares in issue 117,088,657).  

2.   Details of the votes received on the resolutions are available on the Company's website: https://www.shieldtherapeutics.com/investors/corporate-documents/.

3.   Shield Therapeutics plc LEI: 213800G74QWY15FC3W71

- Ends -

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Carl Sterritt, Chief Executive Officer	+44 (0)20 7186 8500
Tim Watts, Chief Financial Officer
Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden	+44 (0)20 7418 8900
Joint Broker
finnCap Ltd	+44 (0)20 7220 0500
Geoff Nash /Matt Radley/ Alice Lane
Walbrook PR	+44 (0)20 7933 8780 or shield@walbrookpr.com
Paul McManus / Helen Cresswell	+44 (0)7980 541 893 / +44 (0)7841 917 679

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs.  The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.  Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.  For more information please visit www.shieldtherapeutics.com. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGCKNDDNBKDQAD